公开(公告)号：US20190307801A1

公开(公告)日：2019-10-10

申请号：US16421111

申请日：2019-05-23

Applicant: Immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WEIBE ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K35/17 ,  C07K14/74 ,  C07K16/30 ,  A61K39/00 ,  C07K14/47 ,  C12N5/0783 ,  C07K16/28

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180055883A1

公开(公告)日：2018-03-01

申请号：US15686679

申请日：2017-08-25

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WEIBE ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/47 ,  C07K16/28 ,  C07K14/74 ,  C07K16/30 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K39/0011 ,  C07K14/4748 ,  C07K14/70539 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/3053 ,  C12N5/0636 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.